Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Growth (Status and Outlook) 2022-2028
![](/report_cover/10189/global-castration-resistant-prostate-cancer-crpchrpca-therapeutics-market-growth-status-n-outlook-2020-2025_en.gif)
The report requires updating with new data and is sent in 48 hours after order is placed.
As the global economy mends, the 2021 growth of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics will have significant change from previous year. According to our (LP Information) latest study, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is USD million in 2022 from USD 7467.6 million in 2021, with a change of % between 2021 and 2022. The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size will reach USD 10790 million in 2028, growing at a CAGR of 5.4% over the analysis period.
The United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market, reaching US$ million by the year 2028. As for the Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics players cover Astellas Inc., Johnson & Johnson, Sanofi S.A, and Dendreon Corporation, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
As the global economy mends, the 2021 growth of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics will have significant change from previous year. According to our (LP Information) latest study, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is USD million in 2022 from USD 7467.6 million in 2021, with a change of % between 2021 and 2022. The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size will reach USD 10790 million in 2028, growing at a CAGR of 5.4% over the analysis period.
The United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market, reaching US$ million by the year 2028. As for the Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics players cover Astellas Inc., Johnson & Johnson, Sanofi S.A, and Dendreon Corporation, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
- Oral Therapy
- Injectable Therapy
- Hospitals & Clinics
- Home Settings
- Ambulatory Surgical Centers (ASCs)
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Astellas Inc.
- Johnson & Johnson
- Sanofi S.A
- Dendreon Corporation
- Bayer AG
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2028
2.1.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Type
2.2.1 Oral Therapy
2.2.2 Injectable Therapy
2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
2.3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
2.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Application
2.4.1 Hospitals & Clinics
2.4.2 Home Settings
2.4.3 Ambulatory Surgical Centers (ASCs)
2.5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
2.5.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
3 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Players
3.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2020-2022)
3.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Players (2020-2022)
3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS BY REGIONS
4.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions (2017-2022)
4.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
5 AMERICAS
5.1 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022)
5.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
5.3 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022)
6.2 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
6.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Country (2017-2022)
7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Region (2017-2022)
8.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
8.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET FORECAST
10.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Regions (2023-2028)
10.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Regions (2023-2028)
10.1.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Country (2023-2028)
10.2.1 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.2 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.3 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.4 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Region (2023-2028)
10.3.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.2 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.3 Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.4 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.5 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.6 Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Country (2023-2028)
10.4.1 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.2 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.3 UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.4 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.5 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Region (2023-2028)
10.5.1 Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.2 South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.3 Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.4 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.5 GCC Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.6 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Type (2023-2028)
10.7 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Application (2023-2028)
11 KEY PLAYERS ANALYSIS
11.1 Astellas Inc.
11.1.1 Astellas Inc. Company Information
11.1.2 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Astellas Inc. Main Business Overview
11.1.5 Astellas Inc. Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Sanofi S.A
11.3.1 Sanofi S.A Company Information
11.3.2 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Sanofi S.A Main Business Overview
11.3.5 Sanofi S.A Latest Developments
11.4 Dendreon Corporation
11.4.1 Dendreon Corporation Company Information
11.4.2 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Dendreon Corporation Main Business Overview
11.4.5 Dendreon Corporation Latest Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Information
11.5.2 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Bayer AG Main Business Overview
11.5.5 Bayer AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2028
2.1.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Type
2.2.1 Oral Therapy
2.2.2 Injectable Therapy
2.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type
2.3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
2.4 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Segment by Application
2.4.1 Hospitals & Clinics
2.4.2 Home Settings
2.4.3 Ambulatory Surgical Centers (ASCs)
2.5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application
2.5.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
3 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET SIZE BY PLAYER
3.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Players
3.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2020-2022)
3.1.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Players (2020-2022)
3.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS BY REGIONS
4.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions (2017-2022)
4.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
4.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth (2017-2022)
5 AMERICAS
5.1 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022)
5.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
5.3 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022)
6.2 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
6.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Country (2017-2022)
7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Region (2017-2022)
8.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022)
8.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL CASTRATION-RESISTANT PROSTATE CANCER (CRPC)/HRPCA THERAPEUTICS MARKET FORECAST
10.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Regions (2023-2028)
10.1.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Regions (2023-2028)
10.1.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.1.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast
10.2 Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Country (2023-2028)
10.2.1 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.2 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.3 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.2.4 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3 APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Region (2023-2028)
10.3.1 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.2 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.3 Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.4 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.5 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.3.6 Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Country (2023-2028)
10.4.1 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.2 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.3 UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.4 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.4.5 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Region (2023-2028)
10.5.1 Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.2 South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.3 Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.4 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.5.5 GCC Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast
10.6 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Type (2023-2028)
10.7 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Forecast by Application (2023-2028)
11 KEY PLAYERS ANALYSIS
11.1 Astellas Inc.
11.1.1 Astellas Inc. Company Information
11.1.2 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Astellas Inc. Main Business Overview
11.1.5 Astellas Inc. Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Sanofi S.A
11.3.1 Sanofi S.A Company Information
11.3.2 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 Sanofi S.A Main Business Overview
11.3.5 Sanofi S.A Latest Developments
11.4 Dendreon Corporation
11.4.1 Dendreon Corporation Company Information
11.4.2 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Dendreon Corporation Main Business Overview
11.4.5 Dendreon Corporation Latest Developments
11.5 Bayer AG
11.5.1 Bayer AG Company Information
11.5.2 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
11.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Bayer AG Main Business Overview
11.5.5 Bayer AG Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Oral Therapy
Table 3. Major Players of Injectable Therapy
Table 4. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 7. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Player (2020-2022)
Table 12. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Products Offered
Table 13. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Regions (2017-2022)
Table 18. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country (2017-2022)
Table 20. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 22. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 24. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region (2017-2022)
Table 26. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 28. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 30. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country (2017-2022)
Table 32. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 34. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 43. Key Market Challenges & Risks of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 44. Key Industry Trends of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 45. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Application (2023-2028)
Table 51. Astellas Inc. Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 52. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 53. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Astellas Inc. Main Business
Table 55. Astellas Inc. Latest Developments
Table 56. Johnson & Johnson Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 57. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 58. Johnson & Johnson Main Business
Table 59. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Johnson & Johnson Latest Developments
Table 61. Sanofi S.A Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 62. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 63. Sanofi S.A Main Business
Table 64. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. Sanofi S.A Latest Developments
Table 66. Dendreon Corporation Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 67. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 68. Dendreon Corporation Main Business
Table 69. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Dendreon Corporation Latest Developments
Table 71. Bayer AG Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 72. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 73. Bayer AG Main Business
Table 74. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. Bayer AG Latest Developments
Table 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Oral Therapy
Table 3. Major Players of Injectable Therapy
Table 4. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 7. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Player (2020-2022)
Table 12. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Key Players Head office and Products Offered
Table 13. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Regions (2017-2022)
Table 18. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country (2017-2022)
Table 20. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 22. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 24. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region (2017-2022)
Table 26. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 28. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 30. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country (2017-2022)
Table 32. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 34. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 43. Key Market Challenges & Risks of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 44. Key Industry Trends of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
Table 45. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share Forecast by Application (2023-2028)
Table 51. Astellas Inc. Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 52. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 53. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Astellas Inc. Main Business
Table 55. Astellas Inc. Latest Developments
Table 56. Johnson & Johnson Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 57. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 58. Johnson & Johnson Main Business
Table 59. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Johnson & Johnson Latest Developments
Table 61. Sanofi S.A Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 62. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 63. Sanofi S.A Main Business
Table 64. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. Sanofi S.A Latest Developments
Table 66. Dendreon Corporation Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 67. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 68. Dendreon Corporation Main Business
Table 69. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Dendreon Corporation Latest Developments
Table 71. Bayer AG Details, Company Type, Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Area Served and Its Competitors
Table 72. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product Offered
Table 73. Bayer AG Main Business
Table 74. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. Bayer AG Latest Developments
LIST OF FIGURES
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 7. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Hospitals & Clinics
Figure 8. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Hospitals & Clinics (2017-2022) & ($ Millions)
Figure 9. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Home Settings
Figure 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Home Settings (2017-2022) & ($ Millions)
Figure 11. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Ambulatory Surgical Centers (ASCs)
Figure 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Ambulatory Surgical Centers (ASCs) (2017-2022) & ($ Millions)
Figure 13. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Player in 2021
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 17. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 18. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 20. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Value Market Share by Country in 2021
Figure 21. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Market Share by Type in 2021
Figure 22. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 23. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region in 2021
Figure 28. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 29. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country in 2021
Figure 36. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 37. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 38. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 46. Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 52. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 53. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 55. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 56. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 59. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 60. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 61. Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 63. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 64. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 65. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 66. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 67. UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 68. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 69. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 70. Spain Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 73. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 74. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 7. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Hospitals & Clinics
Figure 8. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Hospitals & Clinics (2017-2022) & ($ Millions)
Figure 9. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Home Settings
Figure 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Home Settings (2017-2022) & ($ Millions)
Figure 11. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics in Ambulatory Surgical Centers (ASCs)
Figure 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market: Ambulatory Surgical Centers (ASCs) (2017-2022) & ($ Millions)
Figure 13. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 14. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Player in 2021
Figure 15. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Regions (2017-2022)
Figure 16. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 17. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 18. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 19. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2017-2022 ($ Millions)
Figure 20. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Value Market Share by Country in 2021
Figure 21. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Consumption Market Share by Type in 2021
Figure 22. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 23. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 24. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 25. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 26. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 27. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region in 2021
Figure 28. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 29. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 30. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 31. Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 32. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 33. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 34. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 35. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Country in 2021
Figure 36. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 37. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 38. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 39. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 40. UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 41. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 42. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 43. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Region in 2021
Figure 44. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Type in 2021
Figure 45. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Market Share by Application in 2021
Figure 46. Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 47. South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 48. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 49. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 50. GCC Country Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size Growth 2017-2022 ($ Millions)
Figure 51. Americas Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 52. APAC Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 53. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 54. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 55. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 56. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 57. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 58. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 59. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 60. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 61. Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 62. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 63. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 64. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 65. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 66. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 67. UK Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 68. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 69. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 70. Spain Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 71. Egypt Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 72. South Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 73. Israel Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 74. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)
Figure 75. GCC Countries Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size 2023-2028 ($ Millions)